<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

B Cell Acute Lymphoblastic Leukemia Models 
A Champions Model Cohort

Advance your B Cell Acute Lymphoblastic Leukemia (B-ALL) therapeutic candidates using a bank of never-passaged and meticulously curated B-ALL models directly established from primary tumors.

 

 

 Clinically Relevant Models

Living & diverse bank of clinically relevant models that correlate with clinical outcomes

Pretreated PDX Models

Established from tumor biopsies from patients pretreated with latest generation therapies

Multi-omic Characterization

Clinical annotations coupled with molecular datasets and in vivo responses 

 Advance your B Cell Acute Lymphoblastic Leukemia (B-ALL) Therapies

Champions Oncology has developed a comprehensive cohort of patient-derived xenograft (PDX) models for B Cell Acute Lymphoblastic Leukemia (B-ALL) to facilitate translational research and the discovery of novel therapeutic strategies. Our biorepository encompasses a broad spectrum of hematologic malignancies, including ALL, AML, CLL, and MCL, and currently comprises 12* clinically relevant B-ALL PDX models. These models originate from primary patient samples and are engrafted systemically to faithfully recapitulate patient-specific disease characteristics. Notably, most patient-derived samples were obtained post-treatment with Standard of Care regimens.  (*Model numbers fluctuate as our dataset continuously evolves.)

Champions' leading B-ALL cohort showcases primary models, each reflecting key clinical characteristics and pretreatment history. 

  • Rare & well characterized cohort of primary B-ALL models that recapitulates disease biology
  • B-ALL model cohort that can be utilized for successful primary ex vivo studies and PDX in vivo studies
  • Includes models pretreated with advanced cancer therapies post-collection such as CAR-T and those resistant to targeted treatments and the latest immunotherapies.
  • Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
  • Offers comprehensive terminal peripheral blood and bone marrow analysis utilizing Champions' high-complexity flow cytometry endpoint, including markers such as hCD10, hCD45, mCD45, hCD3, hCD19, hCD22, hCD20, and Viability Dye.